Table 2.
Erlotinib | HCX4 - E6/E7 | HCX5 - E6/E7 | HCX6 - E6/E7 | HCX7 - SV40 |
---|---|---|---|---|
untreated | 5/51 | 6/6 | 6/6 | 6/6 |
0.1 μM | 4/6 | 4/6 | 5/6 | 5/6 |
0.3 μM | 3/6 | 2/6 | 2/6 | 4/6 |
1.0 μM | 0/6 | 0/6 | 0/5 | 0/5 |
3.0 μM | 0/4 | 0/6 | 0/6 | 0/6 |
Number of wells with immortal cells/total number of wells examined. Each column represents an independent experiment using cells from a different sample of cervix. All experiments were performed in KSFM plus 5 ng/ml EGF.